Netherlands· NL-de09f0be48ea
Edarclor 40 mg/25 mg, filmomhulde tabletten
A azilsartan medoxomil und diurektika product containing azilsartanmedoxomil kalium + chloortalidon, registered in Netherlands by Takeda Pharma A/S. The same ATC class is registered in 3 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Azilsartan medoxomil und diurektika is registered in 3 of 19 countries.
Countries holding a registration under ATC C09DA09 (azilsartan medoxomil und diurektika), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 1 of them publish a price we can compare per daily dose
Azilsartan medoxomil und diurektika · ATC C09DA09
3 / 19 countries
- Canada
- Netherlands
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- AZILSARTANMEDOXOMIL KALIUM + CHLOORTALIDON
- Manufacturer
- Takeda Pharma A/S
- Country
- Netherlands (NL)
- ATC code
- C09DA09
- ATC class
- Azilsartan medoxomil und Diurektika
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id116387
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
32 interactions on record for azilsartan medoxomil und diurektika.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Azilsartan medoxomil und diurektika · interactions on record
32 records
32 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under C09DA09
Azilsartan medoxomil und diurektika, as other registers publish it.
- SwitzerlandEdarbyclor
- SwitzerlandEdarbyclor
- SwitzerlandEdarbyclor
- SwitzerlandEdarbyclor
- CanadaEDARBYCLORBAUSCH HEALTH, CANADA INC.
- CanadaEDARBYCLORBAUSCH HEALTH, CANADA INC.
- SwitzerlandEdarbyclor 40 mg/12.5 mg, FilmtablettenTakeda Pharma AG
- SwitzerlandEdarbyclor 40 mg/12.5 mg, FilmtablettenTakeda Pharma AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/33b060d2-6fc5-49a0-9500-ba52014a9b97 GET /v1/drugs/33b060d2-6fc5-49a0-9500-ba52014a9b97?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h116387_smpc_en.pdf",
"strength": null,
"atc_label": "Azilsartan medoxomil and diuretics",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg116387",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSPOVIDON (E 1202)",
"FUMAARZUUR (E 297)",
"GRIJZE INKT",
"HYPROLOSE (E 463)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE ROOD (E 172)",
"IJZEROXIDE ZWART (E 172)",
"MACROGOL 8000",
"MAGNESIUMSTEARAAT (E 470b)",
"MANNITOL (D-) (E 421)",
"NATRIUMHYDROXIDE (E 524)",
"SCHELLAK (E 904)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"AZILSARTANMEDOXOMIL KALIUM",
"CHLOORTALIDON"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h116387_piluk.pdf",
"authorised_at": "2015/11/25",
"procedure_number": "NL/H/3333/002",
"dispensing_status": "Uitsluitend recept",
"registration_number": "116387",
"additional_monitoring": "N"
}See everything about azilsartan medoxomil und diurektika.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.